Tafuri, Agostino

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 386

Chronic lymphocytic leukemia cells with mutated nfkbie are positively selected by microenvironmental signals and display reduced sensitivity to ibrutinib treatment

Bonato, A., Bomben, R., Chakraborty, S., Felician, G., Martines, C., Zucchetto, A., Chiarenza, A., Del Poeta, G., Marasca, R., Tafuri, A., et al. (2021) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 3